Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti–PD-1 therapy: MASTERKEY-115,

Autor: Robert, Caroline, Gastman, Brian, Gogas, Helen, Rutkowski, Piotr, Long, Georgina V., Chaney, Marya F., Joshi, Harshada, Lin, Yu-Lin, Snyder, Wendy, Chesney, Jason A.
Zdroj: In European Journal of Cancer August 2024 207
Databáze: ScienceDirect
Externí odkaz: